NEUROENDOCRINE CARCINOMAS
Clinical trials for NEUROENDOCRINE CARCINOMAS explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE CARCINOMAS trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE CARCINOMAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted drug shows promise for tough lung cancers
Disease control Recruiting nowThis study tests a new drug, IDE849, in people with cancers that have a specific marker called DLL3, including small cell lung cancer and other solid tumors. The trial has two phases: first to check safety and find the right dose, then to see if the drug shrinks tumors or slows t…
Matched conditions: NEUROENDOCRINE CARCINOMAS
Phase: PHASE1, PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated May 17, 2026 07:00 UTC
-
New drug ADCT-701 enters first human trial for rare cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called ADCT-701 in about 70 adults with rare neuroendocrine tumors, adrenal cancer, or malignant nerve sheath tumors that have not responded to standard treatments. The drug is given through an IV and aims to deliver a cancer-killing agent …
Matched conditions: NEUROENDOCRINE CARCINOMAS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:59 UTC